ELOVL2

ELOVL2 3'-UTR Variant — The DHA Bottleneck

Your body cannot make DHA from scratch. It relies on a metabolic relay: dietary alpha-linolenic
acid (ALA) from plants is converted step by step — first to EPA, then elongated to DPA, and
finally to DHA. The last two elongation steps in this relay are performed by ELOVL2,
elongation of very long chain fatty acids protein 2 | An endoplasmic reticulum enzyme that
catalyses the rate-limiting elongation of EPA (20:5n-3) to DPA (22:5n-3) and then DPA to DHA
(22:6n-3). DHA is the dominant structural fatty acid in the brain's grey matter and in
photoreceptor cell membranes of the retina. The rs17606561 variant sits in the
3' untranslated region (3'UTR) | The non-coding sequence at the end of an mRNA that controls
message stability, translation efficiency, and miRNA binding — variants here can alter how much
protein a gene produces without changing the protein's sequence of ELOVL2, where it may
influence how efficiently the gene is expressed.

The Mechanism

Unlike missense variants that change ELOVL2's protein structure, this 3'UTR variant likely
affects gene regulation — potentially altering ELOVL2 mRNA stability or its binding to
microRNAs | Small non-coding RNA molecules that bind to mRNA 3'UTR sequences and suppress
translation or promote degradation, fine-tuning protein output. The net effect is a shift
in the EPA→DPA→DHA conversion step. Carriers of the A allele show a pattern consistent with
partial ELOVL2 insufficiency | Lower endogenous DHA synthesis capacity, reflected in reduced
baseline DHA proportions in plasma phospholipids, with upstream EPA and DPA accumulating or
being redirected: lower baseline circulating DHA despite normal EPA intake, with a
compensatory up-regulation of the pathway in response to exogenous EPA/DHA — which is why
minor allele carriers show a larger DHA response to fish oil supplementation.

The Evidence

The clearest evidence for ELOVL2 variants affecting omega-3 metabolism comes from the
CHARGE Consortium meta-analysis | Lemaitre RN et al. Genetic loci associated with plasma
phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the
CHARGE Consortium. PLoS Genet, 2011,
which examined 8,866 subjects of European ancestry across five cohorts. ELOVL2 minor alleles
were robustly associated with higher plasma EPA (p=2×10⁻¹²), much higher DPA
(p=1×10⁻⁴³), and significantly lower DHA (p=1×10⁻¹⁵) — a pattern that precisely matches
a slowdown at the DPA→DHA elongation step: upstream metabolites accumulate while the
downstream product (DHA) is reduced.

A direct supplementation study by
Alsaleh and colleagues | Alsaleh A et al. ELOVL2 gene polymorphisms are associated with
increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil
supplement. Genes Nutr, 2014
in 310 subjects found that ELOVL2 minor allele carriers had lower baseline plasma DHA but
responded more strongly to fish oil supplementation: after 1.8 g/day EPA+DHA, minor allele
carriers achieved approximately 30% higher EPA proportions and 9% higher DHA proportions
than non-carriers. This paradox — lower baseline, larger response — is consistent with
upregulation of an under-expressed enzyme when its substrate (EPA) is sharply increased.

The independent InCHIANTI/GOLDN genome-wide association study
Tanaka et al. | Tanaka T et al. Genome-wide association study of plasma polyunsaturated
fatty acids in the InCHIANTI Study. PLoS Genet, 2009
also identified the ELOVL2 region as a significant locus for plasma n-3 fatty acid levels
in 1,075 elderly Italian subjects, replicated in 1,076 subjects from the GOLDN study.

For rs17606561 specifically, a 2015 birth cohort study
Barman et al. | Barman M et al. Single Nucleotide Polymorphisms in the FADS Gene Cluster
but not the ELOVL2 Gene are Associated with Serum Polyunsaturated Fatty Acid Composition
and Development of Allergy. Nutrients, 2015
found nominally lower 20:4n-6 in cord serum among rs17606561 carriers, though the
association did not survive multiple-testing correction in this smaller cohort (n=211).
A Chinese case-control study
Sun et al. | Sun C et al. FADS1-FADS2 and ELOVL2 gene polymorphisms in susceptibility
to autism spectrum disorders in Chinese children. BMC Psychiatry, 2018
found nominal association between rs17606561 A allele and autism spectrum disorder risk
(OR=1.63, pFDR=0.036), consistent with the known importance of DHA for neurodevelopment,
though this requires replication in larger cohorts.

Practical Actions

The key implication is that A allele carriers rely more heavily on preformed DHA from the
diet because their endogenous synthesis is less efficient. Plant-based omega-3 sources
(flaxseed, chia, walnuts) provide ALA, but the conversion to DHA requires a functional
ELOVL2 step that is partially impaired in A allele carriers. Marine-sourced EPA and DHA —
from fatty fish or algae-based supplements — bypass this bottleneck entirely.

For heterozygous AG individuals, moderate supplementation with preformed EPA/DHA is advisable.
For homozygous AA individuals, the endogenous synthesis impairment is more pronounced; higher
intakes of preformed DHA are particularly important, especially for pregnant women (for fetal
brain development) and older adults (for retinal and cognitive maintenance).

Interactions

ELOVL2 works in concert with FADS1 and FADS2, which handle the earlier desaturation steps
(ALA→SDA→EPA). Variants in FADS1 (rs174547) and FADS2 (rs174537) that reduce desaturase
activity compound with ELOVL2 impairment: reduced input to the elongase (less EPA) combined
with reduced elongase efficiency creates a double bottleneck for DHA synthesis. Individuals
carrying risk alleles in both FADS and ELOVL2 genes have the strongest case for relying
on preformed marine DHA rather than plant-based ALA precursors.